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Abstract Recent cloning of estrogen receptor L (ERL) was
followed by the discovery of a variety of its isoforms. This re-
view describes the complexity of ERL mRNAs in various species
for which most data have been gathered so far. The most sur-
prising ¢nding is the great variation in isoform structure among
various mammalian species. This may re£ect either the fact that
only a very limited number of isoforms have been described so
far or between-species speci¢city, especially as common ele-
ments in closely related species could still be noted. Isoform
variations, as detected mainly at the mRNA sequence level,
should result in profound functional di¡erences at the level of
proteins as already shown in selected cases. Thus, it is proposed
that the diversity of ERL isoforms implies a functional role of
this phenomenon in cellular physiology and pathology of estro-
gen response. & 2002 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Two estrogen receptor types, named ERK and ERL, have
been found to be the major mediators of a variety of biolog-
ical functions of estrogens [1^4]. However, their exact roles
are still poorly elucidated, especially in the case of the recently
discovered ERL [1]. On the other hand, it is becoming increas-
ingly clear that both receptor types are responsible for di¡er-
ent biological functions, as indicated by their speci¢c expres-
sion patterns and various consequences in gene knockouts [5^
8]. Moreover, both ERs work as either homo- or hetero-
dimers, when inducing transcription from gene promoters
equipped with estrogen-responsive elements (ERE) [9^12].
An interesting feature of the ERL and ERK receptors is the
outstanding variety of their mRNA isoforms. The isoforms of
ERK have already been discussed previously [13^15]. In this
review we want to summarize the current knowledge about
the ERL isoforms in selected mammalian species. In order to
provide adequate background information for considering
functional di¡erences between isoforms, we will ¢rst brie£y
summarize the ERL gene and protein structure.
2. ERL: gene and protein structure
ERL was ¢rst cloned in rat [16] and then in human [17]. The
gene is considered to contain eight exons (however, see also
below and Fig. 1) and has a di¡erent chromosomal localiza-
tion from that of ERK [18,19]. The human ERL gene pro-
moter has recently been described, and it is considered to
have at least two major transcription start sites [20]. The hu-
man ERL also has two untranslated exons in the 5P untrans-
lated region of the mRNA transcript [21] and an additional
exon at the 3P region of the gene, which may contribute new
amino acids to the protein [22].
ERL is a member of a nuclear receptor superfamily and
shares a similar overall protein domain structure with the
other members [23]. Starting from the N-terminal end there
is the ¢rst transactivational domain (AF-1) and then the DNA
binding domain (DBD) with a dual zinc ¢nger motif (Fig. 1).
Next there is the hinge (H) domain with a nuclear localization
signal (NLS). The following is the ligand binding domain
(LBD) together with the subsequent second transactivational
domain (AF-2) whose activity, in contrast to AF-1, is ligand-
dependent [24]. There is more than one description of the
structure of the domains and their amino acid content
[19,25]. In this review we will follow the arrangement de-
scribed by Enmark et al. [19]. Initially, the recognition of
ERL function relied mainly on the homology with ERK. How-
ever, further analysis has shown that di¡erences in domain
sequence homology, particularly in AF-1 and AF-2, result
in di¡erential functions [8]. The AF domains interact with a
number of transcriptional cofactors such as steroid receptor
coactivators: SRC-1, SRC-2, SRC-3 [26^30] and a more gen-
eral coactivator, the CREB binding protein (CBP/p300) [31].
The structure of the ERL AF domains and particularly the C-
terminal part of the second AF domain named helix 12 de-
termines the protein’s ability to interact with the coactivators
[32,33].
3. ERL mRNA isoforms
A number of ERL mRNA isoforms have been described,
either in a form of research papers or just as GenBank de-
positions. As there are signi¢cant species variations in this
regard, we will describe them separately for each species. In
each case we will ¢rst present the sequence structure of the
isoforms, next we will analyze a potential protein domain
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composition and its functional consequences, and then present
data on the expression pattern of the isoforms.
3.1. Human ERL mRNA isoforms
The apparent full-length human mRNA encodes 530 amino
acids (aa) and is called hERL1 [34]. Additionally, several full
or partial sequences of other isoforms have been described
to date: hERLcx, hERL2spldel5, hERL3iso, hERL4spl,
hERL5spl, hERLdel2, hERL5del2,5,6, hERLdel3, hERLdel4,
hERLdel5, hERL2,5, hERLdel6, hERLdel2,6, hERLdel2,3,6,
hERLdel5,6 [33^37]. The ¢rst three are described as complete
sequences and for this reason are most likely to be translated
in vivo. The isoform named hERL with C-terminal exchanged
(hERLcx, GenBank AB006589) is also known as ERL 2 splice
variant (hERL2spl, GenBank AF051428). It has a novel se-
quence inserted in place of exon 8 and for the purpose of this
paper we will describe it as composed of two parts: the ¢rst 17
nt, to be called block ‘A’, and the following 92 nt, referred to
as block ‘B’ (Fig. 2). Another isoform was also named
hERL2spl (GenBank AF124790), but it has a di¡erent struc-
ture than that of hERLcx. It resembles the latter by having the
sequences referred above to as block ‘A’ and block ‘B’ instead
of exon 8. However, in addition it has a deletion of exon 5,
hence we will call it hERL2spldel5.
The isoform called hERL3iso (GenBank AF060555) yet
again has a novel sequence instead of exon 8 but it is not
similar to the ones described as block ‘A’ and block ‘B’.
Here we will refer to it as block ‘C’. In addition to the
afore-mentioned full-length clones of mRNA isoforms, the
transcripts described below are reported as incomplete se-
quences, without an identi¢ed translation start sites, and their
structure is shown in Fig. 2, hERL4spl (GenBank AF061054)
and hERL5spl (AF061055). Additionally, isoforms termed
hERLdel2, hERL5del2,5,6, hERLdel3, hERLdel4, hERLdel5,
hERL2,5, hERLdel6, hERLdel2,6, hERLdel2,3,6, hERLdel5,6,
have recently been described [36]. Their schematic representa-
tion is shown in Table 1.
It is important to note that in addition to the afore-men-
tioned isoforms, another level of complexity is provided by
the diversity in the 5P region of the mRNA. There are two
Fig. 1. Structure of the human ERL gene, mRNA, and protein. Gene : exons are shown as thick boxes and introns as thin lines. The numbers
above introns indicate their size in kb. mRNA : the digits within boxes designate the exon number; the numbers below indicate the length of
each exon size in nucleotides; vertical dotted lines between mRNA and protein point to protein domain junctions. Protein : the names above
the scheme designate the protein domains. The AF-1 domain is considered to be responsible for transcription transactivation. The DNA bind-
ing domain (DBD) binds the DNA regulatory sequence named ERE. The hinge domain (H) is responsible for protein £exibility allowing di¡er-
ent spatial conformations and it contains a putative nuclear localizing signal (NLS). The ligand binding domain (LBD) is responsible for ligand
binding. The second transactivation domain (AF-2) is involved in recruiting the ligand to LBD. The numbers within boxes show the number of
amino acids for each domain, numbers below indicate the total size of the protein in amino acids.
Fig. 2. Schematic representations of mammalian ERL mRNA isoforms with inserts. mRNAs are presented as boxed lines. Boxes designate
exons and shaded areas re£ect the encoded protein domains. Respective exon numbers and domain names are indicated at the top. Inserted se-
quences are shown as boxes and shaded or marked with letters A, B, C, D, E (see the main body of the text for details). The thin line bridges
designate exon deletions. The arrows point to location of stop codons. Question marks indicate the nucleotide submission ends within the read-
ing frame. Numbers below show the amino acid count per protein domain for particular species. Isoform names are on the right of the respec-
tive sequence.
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alternatively spliced exons contributing to this part of mRNA.
The ¢rst exon is termed ‘0N’ [21] and is present in the ERL1
transcript [17,20,34]. In contrast the hERLcx transcript lacks
this exon ‘0N’ but instead has yet another untranslated exon
named ‘0K’ [22]. Since these exons do not contribute directly
to the protein open reading frame their signi¢cance remains
unknown.
The protein encoded by hERLcx has all the domains of
hERL1 except the terminal part of the LBD (33 aa out of
274) along with the entire AF-2 domain (28 aa) [22]. The
deletion removes the amino acids encoding helix 12, which
is replaced by 25 new amino acids from the inserted nucleo-
tide sequence. The lack of helix 12 suggests that ERLcx prod-
uct is unable to interact with the coactivators while still dis-
playing the DNA and ligand binding ability.
The functional experiments on this product have given
equivocal results. The data obtained by Ogawa et al. [22]
suggest that hERLcx has no ligand binding a⁄nity, whereas
Moore et al. [34] reported such a property. Additionally this
isoform does not show ligand-dependent transactivation abil-
ity of the ERE-containing promoter [22]. hERLcx forms a
dimer preferentially with hERK rather than hERL, inhibiting
DNA binding by hERK. Therefore, it is considered to act as a
selective inhibitor of estrogen activity via hERK transactiva-
tion [22]. The deletion of the ¢fth exon in the hERL2spldel5
isoform results in a frameshift and a termination of the poly-
peptide chain with 5 aa after the exon 4/5 border. The
hERL2spldel5 protein lacks 264 out of 274 aa of the LBD
together with the AF-2 domain, and has no ligand binding
a⁄nity [37]. Moreover, hERL2spldel5 by itself has no e¡ect
on ERE transcriptional activation, but it does act as a dom-
inant negative receptor, inhibiting the estrogen-mediated tran-
scription through both ERK and ERL [36]. The ERL3iso tran-
script again alters the amino acid sequence of the LBD and of
the second transactivation domain. The insert encodes a 43
amino acid tail at the C-terminus. hERL3iso can bind to the
ERE promoter in a gel shift assay as a homodimer, and can
also bind as a heterodimer with proteins described here as
hERL1 and hERLcx [34].
The expression patterns of human ERL mRNA isoforms
have been determined mostly by RT-PCR [22,34] and by the
use of antibodies directed against the N- [38,39] or C-terminus
[22]. hERL1 is mainly expressed in testis, ovary, uterus, and
spleen. hERLcx was found predominantly in spleen, thymus,
testis, ovary, and colon. Moreover, it is predominantly ex-
pressed in breast cancer tissue at higher levels than ERL1
[35]. hERL3iso transcript was found in a testis cDNA library
only. hERL2spldel5 was found mainly in mammary gland
[40]. There are also several studies describing hERL isoform
expression in human cancer tissues suggesting their in£uence
on tumor progression [39,41^47]. Unfortunately the concen-
tration of alternative ERL mRNAs, relative to that of the
wild-type homologue, was not determined, and the expression
of alternative forms of the ERL protein was not evidenced.
3.2. Marmoset and macaque ERL transcripts
Only limited information is available on ERL expression in
other primates, that is in macaque [48,49] and in marmoset
[50,51]. Two recent submissions to the GenBank provide the
¢rst information on ERL isoform transcripts found in those
species. The sequences for stump-tailed macaque Macaca arc-
toides (AF393815) and white-tufted-ear (common) marmoset
Callithrix jacchus (AF393816) have exactly the same design as
the human ERLcx isoform (Fig. 2). More interestingly, the
amino acids introduced by alternative splicing in place of
exon 8 share signi¢cant similarity (12 out of 15 subsequent
amino acids) in all three species of primates studied to date.
3.3. Rat ERL mRNA isoforms
In the rat, the originally identi¢ed mRNA has been named
rERL1 [16]. In addition, four mRNA isoforms, named rERL2,
rERL1N3, rERL2N3, and rERL1N4, have been identi¢ed to
date [52^55]. The predicted mRNA isoforms encoding puta-
tive proteins are shown in Fig. 2 and Table 1. The rERL1
Table 1
The protein structure of ERL isoforms characterized by exon deletions
Isoform name Protein domains of human ERL Reference
AF-1 (148) DBD (66) H (90) LBD (196) AF-2 (30)
hERLdel2 126* 0 0 0 0 [36]
hERLdel2,5,6 126* 0 0 0 0 [36]
hERLdel2,5 126* 0 0 0 0 [36]
hERLdel2,6 126* 0 0 0 0 [36]
hERLdel2,3,6 126* 0 0 0 0 [36]
hERLdel3 148 30 90 196 30 [36]
hERLdel4 148 66 3 183 30 [36]
hERLdel5 148 66 90 13* 0 [36]
hERLdel5,6 148 66 90 105 30 [36]
hERLdel6 148 66 90 59* 0 [36]
Protein domains of rat ERL
AF-1 (167) DBD (66) H (90) LBD (198) AF-2 (28)
rERL1del3 167 30 84 198 28 [54]
rERL1del4 ? 66 3 198 ? [55]
Protein domains of mouse ERL
AF-1 (167) DBD (66) H (88) LBD (200) AF-2 (28)
mERLdel5 167 66 88 154* 0 [57]
mERLdel6 ? 66 88 155* 0 [57]
mERLdel5,6 167 66 88 109 28 [57]
Next to the names of the domains at the top, the numbers of their amino acid content is shown in parentheses. The numbers in the table show
the remaining number of amino acid residues in each domain. 0 stands for a missing domain, * indicates the frameshift and truncation of the
polypeptide, ? signi¢es non-availability of appropriate information.
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mRNA sequence represents all eight exons identi¢ed so far in
the ERL gene. rERL2 mRNA contains an additional 54 nt,
located within the reading frame, between exons 5 and 6
[52,53]. Thus, this transcript encodes a protein with 18 addi-
tional amino acids in the LBD. rERL1N3 and rERL2N3 share
a deletion of exon 3, but in rERL2N3 this feature is also
combined with the same 54 nt insert as present in rERL2
[54]. The lack of exon 3 results in de¢ciency of one zinc ¢nger
of the DBD. Another isoform, named rERL1N4, was de-
scribed as an incomplete sequence without the start or stop
codons [55].
The afore-mentioned di¡erences among the mRNA iso-
forms produce characteristic functional consequences for the
encoded proteins. Speci¢cally, insertion of 18 aa in the LBD
in rERL2 and rERL2N3 causes a dramatic loss of ligand bind-
ing a⁄nity, when compared to the receptor encoded by rERL1
[54], and unlike the full transcript protein the rERL2 was
unable to interact with SRC-1 transcription coactivator [56].
Furthermore, under conditions in which rERL1 was acting as
the transcriptional activator, rERL2 behaved as a dominant
negative regulator of estrogen action. rERL2 acts as a homo-
dimer and it does not have the ability to induce transcription,
and even inhibits transcriptional activity of rERK and rERL1
[53]. However, in another study, rERL2 was found to be ca-
pable of activating transcription in response to estradiol, but
it required an approximately 1000-fold greater estradiol con-
centration than that needed to activate rERL1 [56]. Isoforms
without part of the DBD (rERL1N3 and rERL2N3) do not
bind to DNA and hence are apparently not capable of acti-
vating transcription.
As far as the expression patterns of various isoforms are
concerned, RT-PCR-based studies have shown that rERL1
and rERL2 mRNAs coexist in most rat organs, such as the
brain (hippocampus, cortex, hypothalamus), lung, kidney,
ovary, and uterus [54,55]. The ratio of rERL1 to rERL2
mRNA is approximately 1:1 in the prostate, ovary, and
muscle [54]. In the nervous system, the rERL1 mRNA was
found to be more abundant than rERL2. The rERL1N3 and
rERL2N3 mRNA isoforms are expressed in the prostate, ova-
ry, and hypothalamus, although at a lower abundance than
full-length ERL mRNA.
3.4. Mouse ERL mRNA isoforms
In mouse, the originally identi¢ed mRNA has been named
mERL1 [18]. Additionally, four mRNA isoforms named
mERL2, mERLNexon5, mERLNexon6, and mERLNexon5,6
have been identi¢ed to date [57]. The putative proteins en-
coded by these mRNA variants are shown in Fig. 2 and Table
1. The mERL1 sequence represents all eight exons of the ERL
gene. mERL2 mRNA is the variant with an additional 54 nt,
located within the reading frame, between exons 5 and 6 [57].
Thus, the protein encoded by this transcript has an 18 aa
insertion in the LBD. Moreover, the inserted amino acid se-
quence shares signi¢cant (16 out of 18 aa) homology with the
respective insert in the rat ERL2 isoform. Two other isoforms,
mERLNexon5 and mERLNexon6, have a deletion of exon 5 or
6 respectively, but in another isoform mERLNexon5,6 this
feature is combined by deletion of both exons 5 and 6 [57].
mERLNexon5 and mERLNexon6 have a frame shift, which
introduces stop codons into the reading frame [57]. Because
of the deletions, these three isoforms encode proteins lacking
various parts of the LBD. The di¡erences among the mRNA
isoforms cause characteristic functional consequences for the
encoded proteins.
The insertion of 18 amino acids in the LBD in mERL2
causes a 30-fold decrease in ligand binding a⁄nity, when com-
pared with mERL1 [58]. Furthermore, mERL2, acting as a
homodimer, did not display transactivating activity under
conditions in which mERL1 was active [58]. Interestingly,
proteins designated mERL1 and mERL2 were able to bind
to classical ERE both in the presence and in the absence of
a ligand as well as inhibiting transcriptional activity of mERK
and mERL1 [58]. It seems that mERL1 may act as a negative
regulator or a modulator of estrogen action. The functional
signi¢cance of proteins encoded by variants mERLNexon5,
mERLNexon6 and mERLNexon5,6 has not yet been tested. It
appears that proteins with deletion of regions encoded by
exons 5 and/or 6 are unlikely to bind a ligand, because of
partial deletion of the LBD.
RT-PCR studies revealed that two isoforms, mERL1 and
mERL2, are expressed in ovary and lung at similar levels [57].
However, in the placenta, uterus, breast, heart, brain, skin,
and kidney there are higher levels of mERL2 mRNA expres-
sion, relative to mERL1 [57]. Furthermore, mERL2 is ex-
pressed predominantly in the liver, pancreas, gut, and bone
[57].
4. Concluding remarks
From an overview of ERL isoforms some general themes
readily emerge. First, a number of ERL mRNA isoforms are
observed in a variety of mammalian species. However, the
structure of isoforms is not uniform but varies from species
to species. This may re£ect either a possibility for remaining
transcripts to be cloned, or between-species isoform speci¢ci-
ty. On the other hand, some of the isoforms share common
elements between closely related species. For instance, tran-
scripts similar to human ERLcx are found in both macaque
and marmoset. Furthermore, when putatively translated, the
inserts replacing exon 8 share considerable amino acid se-
quence similarity. In both rats and mice, the ERL2 isoforms
have the same feature of a novel insert in LBD between exons
5 and 6. These 18 amino acid elements also show signi¢cant
sequence resemblance. Notably, the above-mentioned inserts
are able to change the ERL function. Speci¢cally, in primates
the ERLcx are apparently characterized by altered interactions
with other components of the transcriptional machinery,
whereas in rodents the binding of the ligand appears to be
mostly a¡ected in the isoforms. In conclusion, the emerging
picture of multiple ERL mRNA isoforms, and thus also a
multitude of di¡erentially built proteins, strongly suggests
their synthesis to be considered as yet another level of com-
plexity of estrogen signaling.
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